Sood Ankita, Baishnab Suman, Gautam Isha, Choudhary Priya, Lang Damanpreet Kaur, Jaura Ravinder Singh, Singh Thakur Gurjeet
Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Inflammopharmacology. 2023 Apr;31(2):773-786. doi: 10.1007/s10787-023-01143-x. Epub 2023 Feb 6.
Diabetic retinopathy is regarded as a common manifestation of diabetes mellitus, being a prominent cause of visual impairment and blindness. This microvascular complication is marked by the appearance of microaneurysms, elevated vascular permeability, capillary blockage, and proliferation of neovasculature. The etiology behind retinopathy is ambiguous and the efficacy of current treatment strategies is minimal. Early diagnosis of this complication using a biomarker with high sensitivity and specificity is very essential for providing better therapeutic strategies. The current available therapeutic options are limited with various adverse effects. Laser treatment is not beneficial in all the situations, economic constraints being the major challenge. Surgical interventions are employed when pharmacotherapy and laser treatment fail. New pharmacological treatments are becoming a necessity for treating the condition. This review highlights the use of various diagnostic tools, emerging biomarkers for early detection of diabetic retinopathy, pathological mechanisms associated with the disease, current therapeutic approaches used and future strategies for more enhanced treatment options and more potent pharmacological actions.
糖尿病视网膜病变被视为糖尿病的常见表现,是视力损害和失明的一个突出原因。这种微血管并发症的特征是出现微动脉瘤、血管通透性升高、毛细血管阻塞和新生血管形成。视网膜病变背后的病因尚不明确,目前治疗策略的疗效甚微。使用具有高灵敏度和特异性的生物标志物对这种并发症进行早期诊断对于提供更好的治疗策略非常重要。目前可用的治疗选择有限且有各种不良反应。激光治疗并非在所有情况下都有益,经济限制是主要挑战。当药物治疗和激光治疗失败时采用手术干预。新的药物治疗正成为治疗该疾病的必要手段。本综述重点介绍了各种诊断工具的使用、用于早期检测糖尿病视网膜病变的新兴生物标志物、与该疾病相关的病理机制、当前使用的治疗方法以及未来增强治疗选择和更有效药理作用的策略。